Clinical Trial Update: Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

View source ↗

Summary

This clinical trial update summarizes a retrospective evaluation of nivolumab as adjuvant therapy for esophageal cancer and gastroesophageal junction cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Esophageal Cancer, Gastroesophageal Junction Cancer | Status: COMPLETED